Evidence by cancer type
Metronomic therapy in ovarian cancer
87 studies and 12 trials indexed. 1 trial is recruiting or about to start.
Compiled automatically by Metronomic.com from PubMed and ClinicalTrials.gov. Automated listing. Each item links to its original source. Last refresh: Nov 15, 2026
Titles appear as published. A listing is not an endorsement, and a single study rarely settles a question. Not medically reviewed. Educational information, not medical advice.
Trials recruiting or starting soon
- Not yet recruitingPhase 2NCT07489300Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal CancerSecond Affiliated Hospital, Zhejiang University, School of Medicine
See all 12 trials for ovarian cancer in the trial finder
Newest studies
- StudyGynecol Oncol2026 Oct 1Real-world clinical efficacy of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in heavily pretreated platinum-resistant ovarian cancer.Smith G, et al.
- ReviewCancer Rep (Hoboken)2026 JulMetronomic Chemotherapy in Ovarian Cancer: Current Scenario and AI-Integrated Future Strategies.Chauhan R, et al.
- ReviewTransl Cancer Res2026 Apr 30Metronomic chemotherapy combined with immunotherapy in solid tumor: a systematic review.Li S, et al.
- StudyAnticancer Res2026 AprAnalysis of Clinical Benefit Using DNG64-CAR-V Chimeric Tumor Targeted Amphotropic RNA Vector in CCNG1 Expressing Cancers.Chawla SP, et al.
- StudyOncol Res Treat2026Patient-Reported Outcome in Metastatic Breast Cancer and Platinum-Resistant Recurrent Ovarian Cancer Patients Treated with Metronomic Cyclophosphamide ± Methotrexate: PROmetronomic.Krajnak S, et al.
- Case reportFront Oncol2025Pembrolizumab combined with lenvatinib and metronomic cyclophosphamide in platinum-resistant ovarian cancer: a case report of durable clinical response.Dai G, et al.
- Case reportGynecol Oncol Rep2025 AugEfficacy of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of platinum resistant recurrent ovarian cancer: a retrospective observational study.Steck AR, et al.
- ReviewDrug Resist Updat2025 JulNovel insights into taxane pharmacology: An update on drug resistance mechanisms, immunomodulation and drug delivery strategies.Beretta GL, et al.
- ReviewDrug Deliv Transl Res2025 JunInnovative landscapes in intraperitoneal therapy of ovarian cancer.Kumar KP, et al.
- StudyInt Cancer Conf J2025 JulLow-dose oral cyclophosphamide with or without bevacizumab treatment in patients with recurrent ovarian and cervical cancer before best supportive care.Kawaguchi Y, et al.
- StudyCureus2024 NovOral Metronomic Therapy: An Effective Palliative Treatment Option for Epithelial Ovarian Cancer.Devi R N, et al.
- ReviewMol Cancer2024 Oct 31Folate-engineered chitosan nanoparticles: next-generation anticancer nanocarriers.Kesharwani P, et al.
- StudyArch Gynecol Obstet2024 OctReal-life clinical benefit of oral metronomic cyclophosphamide administration in elderly and heavily pretreated epithelial ovarian cancer patients.Attianese D, et al.
- ReviewCancer Lett2024 Aug 28"Cyclophosphamide and analogues; a matter of dose and schedule for dual anticancer activities".Delahousse J, et al.
- StudyJ Oncol Pharm Pract2024 JulA retrospective, real-life analysis of metronomic oral single-agent cyclophosphamide for the treatment of platinum-pretreated advanced ovarian carcinoma in Italy.Gebbia V, et al.
- StudyCureus2024 JanEfficacy and Safety of Oral Metronomic Chemotherapy in Recurrent Refractory Advanced Gynaecological Cancer: An Experience From the Regional Cancer Centre of Eastern India.Ghosh R, et al.
- Meta-analysisJ Oncol Pharm Pract2024 JanA review and metanalysis of metronomic oral single-agent cyclophosphamide for treating advanced ovarian carcinoma in the era of precision medicine.Martorana F, et al.
- StudySci Rep2023 Dec 7Tazemetostat in the therapy of pediatric INI1-negative malignant rhabdoid tumors.Vejmelkova K, et al.
- StudyCancer Lett2023 Nov 28Metronomic chemotherapy in ovarian cancer.Garg V and Kumar L
- StudySci Rep2023 Nov 6Metronomic and single high-dose paclitaxel treatments produce distinct heterogenous chemoresistant cancer cell populations.Mejia Peña C, et al.
- StudyGynecol Oncol2023 OctMetronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment.Ao W, et al.
- StudyIndian J Cancer2023 Apr-JunTriple combination of palliative oral metronomic chemotherapy in recurrent and metastatic epithelial ovarian cancer: A retrospective study.Harsh KK, et al.
- StudyCancers (Basel)2023 Feb 7Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer.Wysocki PJ, et al.
- StudyHeliyon2022 AugEffectiveness and toxicity of metronomic oral cyclophosphamide for recurrent or platinum-refractory ovarian cancer: A meta-analysis.Huang L, et al.
- Randomized trialGynecol Oncol2021 AugPazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.Sharma A, et al.
- StudyInt J Gynecol Cancer2021 JulMetronomic oral cyclophosphamide in relapsed ovarian cancer.Spiliopoulou P, et al.
- StudyIndian J Surg Oncol2021 MarA Prospective Study on Metronomic Scheduling of Non-chemotherapeutic Drugs in Advanced Epithelial Ovarian Cancers.Shivdas S, et al.
- Clinical trialJAMA Oncol2021 Jan 1Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.Zsiros E, et al.
- Randomized trialGynecol Oncol2020 DecA phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.Hall MR, et al.
- ReviewTaiwan J Obstet Gynecol2020 JanDose-dense chemotherapy with weekly paclitaxel and 3-weekly carboplatin for recurrent ovarian cancer.Chen WC, et al.
- StudyBirth Defects Res2020 Jan 1Multiple dose treatment reduces cyclophosphamide-induced ovarian follicular loss in mice.Athira VR, et al.
- StudyIndian J Med Res2019 DecOral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis.Sharma A, et al.
- Case reportAnticancer Drugs2019 OctOral metronomic cyclophosphamide in advanced ovarian cancer: long-lasting clinical response in an elderly frailty patient.Villa M, et al.
- StudyJ Control Release2019 Jul 10Enhanced anti-tumor efficacy and safety with metronomic intraperitoneal chemotherapy for metastatic ovarian cancer using biodegradable nanotextile implants.Padmakumar S, et al.
- StudyJ Ovarian Res2019 Apr 25Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer.Cohen S, et al.
- StudyInt J Gynecol Cancer2019 FebPhase Ib with expansion study of olaparib plus weekly (Metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients.Rivkin SE, et al.
- Randomized trialCancer Treat Res Commun2019Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.Gupta R, et al.
- StudyFront Pharmacol2018Metronomic Four-Drug Regimen Has Anti-tumor Activity in Pediatric Low-Grade Glioma; The Results of a Phase II Clinical Trial.Verschuur A, et al.
- StudyCancer Res2018 Jul 15Correction: Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer.
- ReviewExpert Opin Drug Deliv2018 MayIntraperitoneal chemotherapy for ovarian cancer using sustained-release implantable devices.Padmakumar S, et al.
